Annals of Diagnostic Pathology
Volume 13, Issue 4 , Pages 285-290 , August 2009

High-grade serous carcinoma of the ovary

References 

  1. Lee KR, Tavassoli FA, Prat J, et al. Tumours of the ovary and peritoneum. In:  Tavassoli FA,  Devillee P editor. Tumours of the breast and female genital organs. Lyon: IARC Press; 2003;p. 119–124
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  3. Mann WJ. Diagnosis and management of epithelial cancer of the ovary. Am Fam Physician. 1994;49:613–618
  4. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol. 2007;25:2894–2901
  5. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007;25:2902–2908
  6. See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer. 2003;13:701–734
  7. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496–504
  8. Kurman RJ. Blaustein's pathology of the female genital tract. 5th ed.. Baltimore (Md): Springer-Verlag; 2001;
  9. Robey SS, Silva EG, Gershenson DM, McLemore D, el-Naggar A, Ordonez NG. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer. 1989;63:839–847
  10. Gershenson DM, Silva EG, Mitchell MF, Atkinson EN, Wharton JT. Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy. Am J Obstet Gynecol. 1993;168:1178–1187
  11. Kommoss F, Kommoss S, Schmidt D, Trunk MJ, Pfisterer J, du Bois A. Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol. 2005;97:195–199
  12. Hollingsworth HC, Steinberg SM, Silverberg SG, Merino MJ. Advanced stage transitional cell carcinoma of the ovary.. Hum Pathol. 1996;27:1267–1272
  13. Costa MJ, Hansen C, Dickerman A, Scudder SA. Clinicopathologic significance of transitional cell carcinoma pattern in nonlocalized ovarian epithelial tumors (stages 2-4). Am J Clin Pathol. 1998;109:173–180
  14. Silva EG, Robey-Cafferty SS, Smith TL, Gershenson DM. Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol. 1990;93:457–465
  15. Scully RE, Young RH, Clement PB. In: Atlas of tumor pathology. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Washington (DC): Armed Forces Institute of Pathology; 1998;p. 141–151
  16. Montag AG, Jenison EL, Griffiths CT, Welch WR, Lavin PT, Knapp RC. Ovarian clear cell carcinoma: a clinicopathologic analysis of 44 cases. Int J Gynecol Pathol. 1989;8:85–96
  17. Sangoi AR, Soslow RA, Teng NN, Longacre TA. Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential. Am J Surg Pathol. 2008;32:269–274
  18. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503–2512
  19. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19:83–89
  20. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol. 2007;38:1074–1080
  21. Lin F, Shi J, Liu H, Zhang J, Zhang PL, Wang HL, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol. 2008;129:592–605
  22. Silva EG, Tornos C, Bailey MA, Morris M. Undifferentiated carcinoma of the ovary. Arch Pathol Lab Med. 1991;115:377–381
  23. Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology. 2007;39:134–138
  24. Che M, Tornos C, Deavers MT, Malpica A, Gershenson DM, Silva EG. Ovarian mixed-epithelial carcinomas with a microcystic pattern and signet-ring cells. Int J Gynecol Pathol. 2001;20:323–328
  25. Tornos C, Silva EG, Ordonez NG, Gershenson DM, Young RH, Scully RE. Endometrioid carcinoma of the ovary with a prominent spindle-cell component, a source of diagnostic confusion. A report of 14 cases. Am J Surg Pathol. 1995;19:1343–1353
  26. García-Velasco A, Mendiola C, Sánchez-Muñoz A, Ballestín C, Colomer R, Cortés-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol. 2008;10:367–371
  27. Ashouri S, Garcia AA. Current status of signal transduction modulators in the treatment of gynecologic malignancies. Curr Treat Options Oncol. 2007;8:383–392

PII: S1092-9134(09)00030-6

doi: 10.1016/j.anndiagpath.2009.03.005

Annals of Diagnostic Pathology
Volume 13, Issue 4 , Pages 285-290 , August 2009

Article Tools

* Image Usage & Resolution